Effect of omega-3 versus placebo on the clinical and paraclinical situation in patients with refractory epilepsy
Phase 2
- Conditions
- Refractory epilepsy.Epilepsy
- Registration Number
- IRCT201604179014N96
- Lead Sponsor
- Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
(a) age of 18 to 55 years; (b) having refractory epilepsy.
Exclusion criteria: (a) pregnancy or breastfeeding; (b) having underling diseases such as lever disease, kidney disease, active infection, pulmonary disease, hypertension, dementia, and mental retardation; (c) catamenial epilepsy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessing the frequency of seizures. Timepoint: before treatment and every month for 4 months. Method of measurement: by taking history.
- Secondary Outcome Measures
Name Time Method Assessing serum level of interleukin-6. Timepoint: before treatment and 4 months later. Method of measurement: by laboratory test.;Assessing serum level of TNF-a. Timepoint: before treatment and 4 months later. Method of measurement: by laboratory test.;Assessing electroencephalogram changes. Timepoint: before treatment and 4 months later. Method of measurement: by taking electroencephalogram.